YSB Inc (9885) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 17.1% YoY to RMB20,969.7m; gross profit increased 27.2% to RMB2,307.0m, with growth led by Self-operation and improved own-brand mix.

• Profit attributable to owners reached RMB153.0m versus RMB30.0m; non-IFRS Adjusted Net Profit rose 51.2% to RMB237.1m.

Financial highlights

• Revenue was RMB20,969.7m, up 17.1% YoY; cost of sales increased 16.0% to RMB18,662.7m.

• IFRS profit for the year rose to RMB146.0m from RMB15.1m; profit attributable to owners was RMB153.0m versus RMB30.0m.

• Adjusted Net Profit, excluding equity-settled share-based payment expenses and Yikuai acquisition-related expenses, increased 51.2% to RMB237.1m; adjusted margin was 1.1% versus 0.9%.

• Basic EPS was RMB0.224 versus RMB0.047; diluted EPS was RMB0.220 versus RMB0.046. Proposed final dividend was RMB0.110 per share, up from RMB0.075.

Outlook and guidance

• 2026 priorities include deeper digital and AI deployment, stronger supply-chain collaboration, expansion of own brands and grassroots reach, and exploration of on-demand pharmaceutical retail fulfillment.

• Management plans to pursue industrial-chain investments and M&A prudently while maintaining healthy financial conditions; no quantitative earnings guidance was stated.